mRNA-LNP vaccine encoding for Fc-scaffold antigen drives FcgammaR-independent immunity

Authors: Benarroch, Shani; Cohen, Hila; Elia, Uri; Levy, Yinon; Noy-Porat, Tal; Rosenfeld, Ronit; Gur, David; Alcalay, Ron; Shlosberg, Maya; Kundoor, Govinda Reddy; Avraham, Yahel; Goldsmit, Meir; Bar-Haim, Erez; Hazan-Halevy, Inbal; Cohen, Ofer; Dahan, Rony; Mamroud, Emanuelle; Peer, Dan

Source journal: Journal of controlled release : official journal of the Controlled Release Society (2026-11-19)

DOI: 10.1016/j.jconrel.2026.115555

Abstract

While clinical translation of messenger RNA (mRNA) lipid nanoparticle (LNP) technologies has redefined vaccinology, the development of potent platforms against complex bacterial pathogens is often limited by the transient expression kinetics and rapid clearance of encoded antigens. One well established approach to enhance immunogenicity is the fusion of an Fc fragment to an antigen. However, the mechanism of Fc-mediated potentiation within mRNA-LNP systems is, yet, undefined, specifically regarding the necessity of receptor-mediated interactions. Here, we demonstrate that an mRNA-LNP vaccine, encoding an Fc-fragment fused to the Yersinia pestis F1 antigen, drives robust, protective immunity against the lethal bubonic plague by functioning as a pharmacokinetic stabilizer. Through systematic architectural design, variation of Fc isotypes, species-matched scaffolding, and glycosylation profiling, we reveal that Fc-integration extends systemic antigen bioavailability by over 300-fold, providing a sustained kinetic window for immune priming. Remarkably, immunogenicity is preserved in Fcgamma receptor (FcgammaR)-deficient mice, as well as with a reduced FcgammaR-binding Fc variant, suggesting that protective immunity is independent of classical FcgammaR engagement in this model. These findings decouple Fc-mediated enhancement from receptor-mediated interactions, identifying structural stabilization and prolonged persistence as the primary drivers of efficacy in mRNA-LNP vaccines. Altogether, our results provide a mechanistic framework for the design of high-potency mRNA vaccines through engineered protein stability.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.